Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

NANOTEMPER TECHNOLOGIES UNVEILS BIOTINYLATED TARGET LABELING KIT, EMPOWERING SCIENTISTS IN PHARMA INDUSTRY TO TACKLE CHALLENGING DRUG TARGETS

Businesswire | June 30, 2023

news image

NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry. This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the preferred orthogonal me...

Read More

Pharma Tech

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals | January 06, 2021

news image

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More

RED RIVER BIOREFINERY NOW PRODUCING PHARMACEUTICAL GRADE (USP) ETHANOL FOR HAND SANITIZERS AND DISINFECTANTS

Red River Biorefinery | October 06, 2020

news image

The Red River Biorefinery (RRB) announced today that it has expanded production to supply ethanol that meets the U.S. Pharmacopeia (USP) purity and quality standards to the hand sanitizer market. To help meet the increase in global demand for hand sanitizer products due to COVID-19, RRB is now supplying hand sanitizer manufacturers with safe, high-quality ethanol products with one of the lowest carbon footprints available on the market today. It is extremely gratifying to have a local producer s...

Read More

IMMATICS PARTNERS GSK IN DEAL WORTH €1B TO DEVELOP CANCER THERAPIES

Labiotech.eu | February 21, 2020

news image

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive €46M upfront and €509M in undisclosed developmental and commercial milestone payments per program, plus royalties. These thera...

Read More
news image

Pharmacy Market

NANOTEMPER TECHNOLOGIES UNVEILS BIOTINYLATED TARGET LABELING KIT, EMPOWERING SCIENTISTS IN PHARMA INDUSTRY TO TACKLE CHALLENGING DRUG TARGETS

Businesswire | June 30, 2023

NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry. This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the preferred orthogonal me...

Read More
news image

Pharma Tech

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals | January 06, 2021

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More
news image

RED RIVER BIOREFINERY NOW PRODUCING PHARMACEUTICAL GRADE (USP) ETHANOL FOR HAND SANITIZERS AND DISINFECTANTS

Red River Biorefinery | October 06, 2020

The Red River Biorefinery (RRB) announced today that it has expanded production to supply ethanol that meets the U.S. Pharmacopeia (USP) purity and quality standards to the hand sanitizer market. To help meet the increase in global demand for hand sanitizer products due to COVID-19, RRB is now supplying hand sanitizer manufacturers with safe, high-quality ethanol products with one of the lowest carbon footprints available on the market today. It is extremely gratifying to have a local producer s...

Read More
news image

IMMATICS PARTNERS GSK IN DEAL WORTH €1B TO DEVELOP CANCER THERAPIES

Labiotech.eu | February 21, 2020

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive €46M upfront and €509M in undisclosed developmental and commercial milestone payments per program, plus royalties. These thera...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us